Funding in the biotech model from conception through maturity

08/5/2008 | Scientist, The (free registration)

Biotech companies today tend to develop intellectual property and then license or sell it, rather than focusing on an end-stage commercial product. IPOs and venture capital funding for early-stage research have declined in recent years, but pharmaceutical companies increasingly are buying small biotechs' early-stage work to supplement their own pipelines. This analysis looks at the overlay between drug development and the financial life cycle of a biotech firm.

View Full Article in:

Scientist, The (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC